In an era of cancer immunotherapies, the recent introduction of neoantigen cancer vaccine (also referred neovaccines) has garnered new hope in the medical community, owing to their ability to induce the body’s natural defenses against abnormal malignancies. Cancer is very complex to treat. Sometimes target antigens are also present on normal cells and cancerous cells, making the body vulnerable to attacks in the wrong places by the current mainstays of immunotherapies. Ironically, this phenomenon provides an opportunity for neoantigen cancer vaccine to step in and fill up the potential treatment gaps by selectively targeting cancerassociated antigens. Neoantigens are foreign peptides that are totally absent from the normal healthy cells and are specifically identified by neoantigen-specific T-cell receptors in terms of major histocompatibility complexes (MHCs) molecules. Unlike the tumor-associated antigens and cancer germline antigens, normally present on cancer and healthy cells, neoantigens are exclusively present on the tumor tissues and thus provide an initial concept of targeting them.

Conventional minimally invasive surgery has existed for several decades, i.e., since the 1980s. However, the market is constantly being influenced by rapid development in technology, product innovation, and diversification. The rising demand for surgical procedures is primarily attributed to the increasing aging population with one or more chronic disorders. Surgical robotics has been in the market for nearly two decades. The first robotic-assisted surgery system – the da Vinci system manufactured by Intuitive Surgical, Inc., received U.S. FDA approval in 2000. Since then, the market has grown significantly, constantly influenced by technological upgrades. Following is the expected impact on the global market due to key drivers and restraints for the global minimally invasive surgical systems market:

Medical swabs are crucial components in diagnostic tests and are largely used in clinical settings for various other purposes, such as specimen collection, medicine application, equipment maintenance, and wound treatment. The surge in diagnostic and research requirements worldwide has accelerated the use of medical swabs.

The spine is a column of bone and cartilage that extends from the base of the skull to the pelvis and acts as the core of the human skeleton by supporting the head and the rest of the body. The complexity of the spine structure makes it susceptible to various ailments that can lead to instability and significant low back pain.

申万医药生物指数下跌1.38%，整体弱于大盘。其中医疗器械子行业涨幅较大，上涨2.94%；医疗服务子行业上涨2.33%，医药商业子行业下跌2.97%，化学制药子行业下跌3.58%，中药子行业下跌3.82%；生物制品子行业下跌5.17%。上周A 股医药整体震荡下行，仅服务板块因国务院强调扩大重点领域消费，促进医疗健康、养老、托育等服务消费而上涨，展望下周，动态清零仍将持续，国内疫情反复，短期我们仍建议关注国产新冠疫苗、新冠药物研发进展及新冠检测产品及服务等产业链相关公司以及一季报超预期的公司，中期考虑疫情后逐渐复苏以及国家对消费医疗的支持，关注受疫情影响的部分医疗服务和消费医疗的复苏政策以及疫情后新基建的建设进度。

2021年及2022Q1我国疫苗批签发情况总体受新冠疫情影响以及新冠疫苗集中接种影响较大，多数品种实现批签发批次数据有所下降，但部分重磅品种如HPV疫苗、13价肺炎疫苗等仍然实现快速增长。其中，智飞生物代理默沙东四价HPV、九价HPV分别实现批签发38批次（+23%）、42批次（+75%）；代理默沙东五价轮状病毒疫苗实现批签发86批次（+79%）。万泰生物二价HPV疫苗实现163批次（+254%）。康泰生物百白破-Hib四联苗实现批签发42批次（-18%），22Q1康泰13价肺炎疫苗实现12批次批签发。康华生物人二倍体细胞狂犬病疫苗2021年实现批签发60批次（+7%）22Q1实现24批次（+300%）。欧林生物吸附破伤风疫苗实现批签发42批次（-13%）。

2021 年原料药行业相继受到上游原材料涨价、汇率波动、去库存等因素影响，API企业陆续出现经营波动。此外，2021 年人民币升值导致API 出口业务的业绩受到干扰，同时上游原材料价格明显上涨也是导致毛利率下降的重要原因之一。但海外原料药行业相继受到疫情影响，供给收缩，而国内疫情逐渐控制，供应量相对充足，国内原料药企业的出口业务因此获益。

全球疫情下降趋势明显：截至2022年4月10日，全球各洲新增新冠患者均处于下降阶段，亚洲和欧洲在最近的疫情反弹中出现拐点后情况开始缓和。国内疫情防控形势严峻：近期国内疫情多点散发，本土确诊病例和无症状感染者增长迅速。Omicron变异毒株传染性强、传播速度快，并且有一定比例的无症状感染者，给疫情防控带来了新的难点，防控形势日趋严峻复杂。

The adoption of healthcare information technology (HCIT) in the healthcare sector has supported patient engagement and played an instrumental role in reducing medical costs. Nursing was at the forefront of achieving these results and was one of the first users of healthcare IT solutions for interactive patient engagement. Several HCIT solutions such as the interactive patient management systems enable healthcare providers to provide entertainment and educational resources to patients, which results in better care experience across the complete continuum of care.

With the rollout of the vaccine across the world in 2021 the global economy is expected to expand by roughly 4 in 2021 However, in January 2021 the World Bank stated in its Global Economic Prospects that the recovery will be slow unless governments around the world take effective action to control the pandemic and begin implementing investment enhancing reforms, as well as vaccination campaigns, strict health policies, and financial support Within the broader context of e health, telehealth is gaining traction in both developed and developing countries Telehealth has been used in almost every country in the world, but it is embedded in only a few